Showing results (101-110 of 110) with videos related to
Sort By:
Pageof 11
You have reached the last page of results.This site can display upto 110 results.
Chemical Communications (Cambridge, England)|October 2, 2020
Small molecule induced toxic human-IAPP species characterized by NMRSarah J Cox, Diana C Rodriguez Camargo, Young-Ho Lee, et al.British Journal of Cancer|October 10, 2002
Role of biological markers in the clinical outcome of colon cancerO Nanni, A Volpi, G L Frassineti, et al.Neurology|February 1, 1997
Cabergoline in the treatment of early Parkinson's disease: results of the first year of treatment in a double-blind comparison of cabergoline and levodopa. The PKDS009 Collaborative Study GroupU K Rinne, F Bracco, C Chouza, et al.Cell Proliferation|May 15, 2009
Isolation of stem/progenitor cells from normal lung tissue of adult humansA Tesei, W Zoli, C Arienti, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1997
Dose-intensity of a four-drug chemotherapy regimen with or without recombinant human granulocyte-macrophage colony-stimulating factor in extensive-stage small-cell lung cancer: a multicenter randomized phase III studyJ L Pujol, J Y Douillard, A Rivière, et al.The European Respiratory Journal|January 29, 2011
Idiopathic nonspecific interstitial pneumonia: an interstitial lung disease associated with autoimmune disorders?M Romagnoli, C Nannini, S Piciucchi, et al.Sarcoidosis, Vasculitis, and Diffuse Lung Diseases : Official Journal of WASOG|September 28, 2013
The effect of anticoagulant therapy for idiopathic pulmonary fibrosis in real life practiceS Tomassetti, J H Ruy, C Gurioli, et al.Pathologica|September 28, 2018
The 2015 World Health Organization Classification of lung tumors: new entities since the 2004 ClassificationM C Mengoli, F R Longo, F Fraggetta, et al.Blood|May 16, 1998
A placebo-controlled study of recombinant human granulocyte-macrophage colony-stimulating factor administered during and after induction treatment for de novo acute myelogenous leukemia in elderly patients. Groupe Ouest Est Leucémies Aiguës Myéloblastiques (GOELAM)F Witz, A Sadoun, M C Perrin, et al.British Journal of Haematology|August 1, 1996
Treatment of acute myelogenous leukaemia in patients aged 50-65: idarubicin is more effective than zorubicin for remission induction and prolonged disease-free survival can be obtained using a unique consolidation course. The Goelam GroupB Pignon, F Witz, B Desablens, et al.Pageof 11